Pfizer Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.18B | $81.29B | $41.65B | $40.91B | $40.83B |
| Cost of Revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B |
| Gross Profit | $46.51B | $45.78B | $34.60B | $66.83B | $50.47B | $33.17B | $32.85B | $31.84B |
| Gross Margin | 74.3% | 71.9% | 58.1% | 66.1% | 62.1% | 79.6% | 80.3% | 78.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B | $12.61B |
| Operating Income | $10.19B | $11.11B | $3.27B | $35.97B | $25.60B | $8.49B | $12.89B | $4.91B |
| Operating Margin | 16.3% | 17.5% | 5.5% | 35.5% | 31.5% | 20.4% | 31.5% | 12.0% |
| Interest Expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B |
| Pretax Income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B |
| Income Tax Expense | $-266.0M | $-28.0M | $-1.12B | $3.33B | $1.85B | $370.0M | $583.0M | $-266.0M |
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B |
| Net Margin | 12.4% | 12.6% | 3.6% | 31.0% | 27.0% | 22.0% | 39.2% | 27.3% |
| EPS (Basic) | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 | $1.90 |
| EPS (Diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 |
| Shares Outstanding (Basic) | 5.68B | 5.66B | 5.64B | 5.61B | 5.60B | 5.56B | 5.57B | 5.87B |
| Shares Outstanding (Diluted) | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.68B | 5.98B |
| Dividends Per Share | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 | $1.53 | $1.46 | $1.38 |